News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

R-Tech Ueno: Adoption of the Unoprostone Ophthalmic Solution in the 3rd A-STEP Public Recruitment in FY2012


2/1/2013 9:13:56 AM

TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573) is pleased to announce that the unoprostone (development code: UF-021) ophthalmic solution currently in development as a treatment of retinitis pigmentosa Note 1 (product name: OcusevaTM) has been adopted in the Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-STEP) public recruitment as "Full-scale R&D Stage - Practical Application Type (Contract Development) Note 2" by the Japan Science and Technology Agency (JST) and that we have concluded an agreement on new technology contract development, etc. with JST today.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES